4basebio (LON:4BB) Given Outperform Rating at Royal Bank Of Canada

4basebio (LON:4BB)‘s stock had its “outperform” rating reiterated by analysts at Royal Bank Of Canada in a research note issued on Thursday,London Stock Exchange reports. They currently have a GBX 1,600 price target on the stock. Royal Bank Of Canada’s target price points to a potential upside of 113.19% from the company’s previous close.

4basebio Stock Performance

LON 4BB opened at GBX 750.50 on Thursday. The stock has a market cap of £116.21 million, a PE ratio of -798.40 and a beta of 1.09. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. 4basebio has a twelve month low of GBX 704.50 and a twelve month high of GBX 1,500. The stock has a fifty day simple moving average of GBX 877.32 and a 200-day simple moving average of GBX 1,012.76.

4basebio (LON:4BB) last released its earnings results on Monday, September 29th. The company reported GBX (50) earnings per share for the quarter. Equities analysts anticipate that 4basebio will post -3.43 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Heikki Lanckriet purchased 2,000 shares of the business’s stock in a transaction on Monday, September 29th. The shares were bought at an average price of GBX 749 per share, with a total value of £14,980. 12.02% of the stock is currently owned by company insiders.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.